Clexio Biosciences trades on the FSE under the symbol
Clexio Biosciences is a multi-asset, CNS-first clinical stage pharmaceutical company with a broad and growing pipeline. Clexio is dedicated to developing novel therapies for patients suffering from neurological and psychiatric conditions.
Clexio is developing novel therapies to address patients’ unmet needs in Major Depressive Disorder, Chronic Pruritus of neurological origin, Neuropathic Pain, Cluster Headache and Parkinson ’s disease. Their lead drug candidate is currently in a Phase II multicenter study in the United States.
One of their driving principles is to invent new therapeutic modalities and bring them quickly from an idea to Proof of Concept and then to full clinical development. Clexio identifies points of convergence between validated mechanisms of action and technology, to generate new patient-centric possibilities.
Clexio Biosciences multidisciplinary team brings years of experience in the Pharmaceutical and Biotech industries and encompasses end-to-end drug development expertise, from early stage to advanced clinical stages and regulatory approvals.
GET THE HEADLINES + UPDATES
Be the first to see new company features, exclusive interviews and breaking news. Subscribe now.